Prostate Cancer 2008: Challenges in Diagnosis and Management

European Urology, Supplements

Volumn 8, Issue 3, 2009, Pages 89-96

  Marberger, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; EDITORIAL; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

EID: 57049144758     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.10.003     Document Type: Editorial

References (53)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Etzioni R., Gulati R., Falcon S., and Penson D.F. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modelling approach. Med Decis Making 28 (2008) 324-331
3. Harris R., and Lohr K.N. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Service Task Force. Ann Intern Med 137 (2002) 917-929
4. Etzioni R., and Feuer E. Studies of prostate-cancer mortality: caution advised. Lancet Oncol 9 (2008) 407-409
5. Bosetti C., Bertuccio P., Levi F., Lucchini F., Negri E., and La Vaecchia C. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 19 (2008) 631-640
6. Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., and Coebergh J.W.W. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990's. Eur J Cancer 44 (2008) 1345-1389
7. Bouchardy C., Fioretta G., Rapiti E., et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 123 (2008) 421-429
8. Bartsch G., Horninger W., Klocker H., et al. Tyrol Prostate Cancer Screening Group. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101 (2008) 809-816
9. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8 (1994) 439-443
10. Epstein J.I., Walsh P.C., Carmichael M., and Brendler C.B. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
11. Draisma G., Postma R., Schröder F.H., van der Kwast T.H., and de Koning H.J. Gleason score, age and screening: modelling dedifferentiation in prostate cancer. Int J Cancer 119 (2006) 2366-2371
12. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early localized prostate cancer. JAMA 291 (2004) 2713-2719
13. Albertsen P.C. The face of high risk prostate cancer. World J Urol 26 (2008) 205-210
14. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
15. Vutuc C., Waldhoer T., Sevelda P., Miksche M., and Haidinger G. Self-reported prostate cancer screening in Austria. J Med Screen 13 (2006) 148-151
16. Vutuc C, Haidinger G. Epidemiology of prostate cancer in Austria. J Med Screening. Submitted.
17. Epstein J.I., Sanderson H., Carter H.B., and Scharfstein D.O. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 66 (2005) 356-360
18. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246
19. Hernández J., and Thompson I.M. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101 (2004) 894-904
20. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
21. Stenman U.H., Abrahamsson P.A., Aus G., et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl 39 (2005) 64-91
22. Schröder F.H., Carter H.B., Wolters T., et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 53 (2008) 468-477
23. Ramirez M.L., Nelson E.C., Devere White R.W., Lara Jr. P.N., and Evans C.P. Current applications for prostate-specific antigen doubling time. Eur Urol 54 (2008) 291-302
24. Roemeling S., Roobol M.J., de Vries S.H., et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics PSA doubling times, and outcome. Eur Urol 51 (2007) 1244-1251
25. Djavan B., Ravery V., Zlotta A., et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol 166 (2001) 1679-1683
26. Remzi M., Fong Y.K., Dobrovits M., et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 174 (2005) 1256-1260
27. Djavan B., Rocco B., Ravery V., et al. Pathological and biochemical features of cancers detected on saturation biopsies in men with PSA levels 2.5-10ng/ml and negative initial biopsies: a multiinstitutional European study. Eur Urol Suppl 6 (2007) 197
28. Kattan M.W., Eastham J.A., Wheeler T.M., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
29. Roemling S., Roobol M.J., Kattan M.W., van der Kwast T.H., Steyerberg E.W., and Schröder F.H. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer 110 (2007) 2218-2221
30. Nelson W.G. Prostate cancer prevention. Curr Opin Urol 17 (2007) 157-167
31. Kramer G., Mitteregger D., and Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol 51 (2007) 1202-1216
32. De Marzo A.M., Marchi V.L., Epstein J.I., and Nelson W.G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155 (1999) 1985-1992
33. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
34. Shimizu H., Ross R.K., Bernstein L., Yatani R., Henderson B.E., and Mack T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63 (1991) 963-966
35. Heinonen O.P., Albanes D., Virtamo J., et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90 (1998) 440-446
36. Klein E.A., Thompson I.M., Lippman S.M., et al. SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 166 (2001) 1311-1315
37. Van Adelsberg J., Gann P., Ko A.T., et al. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 23 (2007) 2063-2070
38. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (2004) 1314-1317
39. Cooperberg M.R., Broering J.M., Litwin M.S., et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171 (2004) 1393-1401
40. Damber J.E. Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?. BJU Int 93 (2004) 695-701
41. Lu-Yao G.L., Albertsen P.C., Moore D.F., et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300 (2008) 173-181
42. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 24 (2006) 1868-1876
43. Schmitt B, Bennett C, Seidenfeldt J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000:CD001526.
44. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227
45. Titus M.A., Schell M.J., Lith F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4653-4657
46. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
47. Hellerstedt B.A., and Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52 (2002) 154-179
48. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571
49. Berthold D.R., Pond G.R., de Wit R., Eisenberger M., Tannock I.F., and On behalf of the TAX 327 investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19 (2008) 1749-1753
50. Berthold D.R., Pond G.R., Roessner M., de Wit R., Eisenberger M., and Tannock A.I. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14 (2008) 2763-2767
51. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., and Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 (2007) 6396-6403
52. Olbert P.J., Hegele A., Kraeuter P., Heidenreich A., Hofmann R., and Schrader A.J. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 17 (2006) 993-996
53. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008) 1148-1159